JP6490574B2 - 不溶性フィブリンに対する抗体 - Google Patents
不溶性フィブリンに対する抗体 Download PDFInfo
- Publication number
- JP6490574B2 JP6490574B2 JP2015503025A JP2015503025A JP6490574B2 JP 6490574 B2 JP6490574 B2 JP 6490574B2 JP 2015503025 A JP2015503025 A JP 2015503025A JP 2015503025 A JP2015503025 A JP 2015503025A JP 6490574 B2 JP6490574 B2 JP 6490574B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fibrinogen
- fibrin
- amino acid
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013039625 | 2013-02-28 | ||
| JP2013039625 | 2013-02-28 | ||
| PCT/JP2014/054925 WO2014133093A1 (ja) | 2013-02-28 | 2014-02-27 | 不溶性フィブリンに対する抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018137861A Division JP7012360B2 (ja) | 2013-02-28 | 2018-07-23 | 不溶性フィブリンに対する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2014133093A1 JPWO2014133093A1 (ja) | 2017-02-02 |
| JP6490574B2 true JP6490574B2 (ja) | 2019-03-27 |
Family
ID=51428352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503025A Active JP6490574B2 (ja) | 2013-02-28 | 2014-02-27 | 不溶性フィブリンに対する抗体 |
| JP2018137861A Active JP7012360B2 (ja) | 2013-02-28 | 2018-07-23 | 不溶性フィブリンに対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018137861A Active JP7012360B2 (ja) | 2013-02-28 | 2018-07-23 | 不溶性フィブリンに対する抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9429584B2 (enExample) |
| EP (2) | EP3339327A3 (enExample) |
| JP (2) | JP6490574B2 (enExample) |
| ES (1) | ES2673583T3 (enExample) |
| WO (1) | WO2014133093A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016167227A1 (ja) * | 2015-04-13 | 2016-10-20 | 国立研究開発法人国立がん研究センター | 不溶性フィブリンに対する抗体 |
| TWI617319B (zh) | 2015-09-01 | 2018-03-11 | 免疫功坊股份有限公司 | 用以治療病理性血栓的融合蛋白 |
| AU2017360168B2 (en) | 2016-11-18 | 2023-10-12 | Astellas Pharma Inc. | Novel anti-human MUC1 antibody Fab fragment |
| MY191926A (en) | 2016-12-01 | 2022-07-18 | Regeneron Pharma | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| WO2018148476A1 (en) | 2017-02-10 | 2018-08-16 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| JP7204132B2 (ja) * | 2017-05-02 | 2023-01-16 | 国立研究開発法人国立がん研究センター | プラスミンにより切断可能な抗不溶性フィブリン抗体と薬物とのコンジュゲート |
| TWI795415B (zh) * | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
| KR102880156B1 (ko) | 2017-07-24 | 2025-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 항cd8 항체 및 이의 용도 |
| US12202908B2 (en) | 2018-05-17 | 2025-01-21 | Astellas Pharma Inc. | Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand |
| AU2019343131A1 (en) * | 2018-09-17 | 2021-04-29 | Icahn School Of Medicine At Mount Sinai | Anti-LILRB2 antibodies and methods of use thereof |
| MX2021004146A (es) | 2018-10-10 | 2021-06-08 | Astellas Pharma Inc | Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado. |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
| CN115461462B (zh) * | 2020-03-31 | 2024-11-29 | 国立研究开发法人国立癌症研究中心 | 与纤维蛋白结合的抗体及含有该抗体的药物组合物 |
| US12509507B2 (en) | 2020-03-31 | 2025-12-30 | National Cancer Center | Fusion protein suitable for dissolving fibrin clot, and pharmaceutical composition containing said fusion protein |
| EP3916009B1 (en) * | 2020-05-26 | 2023-06-28 | Sartorius Lab Instruments GmbH & Co. KG | Recombinant proteins based on fibrinogen |
| WO2023195535A1 (ja) | 2022-04-08 | 2023-10-12 | 株式会社凜研究所 | フィブリンに結合する抗体および当該抗体を含むフィブリン溶解性タンパク質および当該タンパク質を含む医薬製剤 |
| CN118240085B (zh) * | 2022-10-08 | 2025-05-09 | 东莞市朋志生物科技有限公司 | 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4916070A (en) | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
| US5120834A (en) * | 1988-06-13 | 1992-06-09 | American Biogenetic Sciences, Inc. | Fibrin-specific monoclonal antibody |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| JPH11206387A (ja) | 1991-08-28 | 1999-08-03 | Genpharm Internatl Inc | 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| HU221385B1 (en) | 1994-07-13 | 2002-09-28 | Chugai Pharmaceutical Co Ltd | Reconstituted human antibody against human interleukin-8 |
| KR19990008197A (ko) | 1995-04-28 | 1999-01-25 | 레이몬드 엠. 위티 | 면역화된 제노마우스 유래의 인체 항체 |
| JPH08301900A (ja) | 1995-04-28 | 1996-11-19 | Shima Kenkyusho:Kk | 可溶性フィブリン複合体に対するモノクローナル抗体 |
| JPH09104700A (ja) | 1995-10-09 | 1997-04-22 | Bio Rinkusu Kk | 抗ヒト可溶性フィブリン抗体及びそれを用いた免疫学的測定法 |
| JP2001354700A (ja) | 2000-06-12 | 2001-12-25 | Bio Links Kk | モノクロ−ナル抗体及びヒトフィブリン分解産物の測定方法 |
| ES2376454T3 (es) | 2000-12-22 | 2012-03-14 | Grad, Carole, Legal Representative Of Howard, Kaplan | Librer�?as de expresión en fago de fragmentos vh humanos. |
| BR0210648A (pt) | 2001-06-26 | 2004-10-05 | Agen Biomedical Ltd | Variante de uma molécula imunointerativa, anticorpo monoclonal, forma disimunizada de anticorpo monoclonal 3b6, método para a geração de um anticorpo monoclonal desimunizado, molécula de anticorpo desimunizada, anticorpo desimunizado, anticorpo monoclonal de murino variante 3b6 desimunizado, variante de um anticorpo monoclonal de murino 3b6 desimunizado para uso em humanos, método para a detecção de um coágulo sanguìneo em um paciente humano, método para a detecção de um coágulo sanguìneo ou de um seu fragmento de ligação a antìgeno, método para a facilitação da dissolução ou da remoção de um coágulo sanguìneo em um humano, uso de um anticorpo monoclonal derivado de murino variante, e, conjugado |
| JP5222521B2 (ja) | 2004-12-28 | 2013-06-26 | 積水メディカル株式会社 | 抗ヒト可溶性フィブリンモノクローナル抗体の製造方法 |
| ES2367032T3 (es) | 2004-12-28 | 2011-10-27 | Sekisui Medical Co., Ltd. | Anticuerpo monoclonal anti-fibrina soluble humana y procedimiento de ensayo inmunológico usando el anticuerpo. |
| US7977314B2 (en) * | 2005-12-02 | 2011-07-12 | Amorfix Life Sciences Limited | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
| NO345996B1 (no) * | 2005-12-12 | 2021-12-13 | Ac Immune Sa | A beta 1-42-spesifikke monoklonale antistoffer med terapeutiske egenskaper. |
| WO2008096760A1 (ja) | 2007-02-05 | 2008-08-14 | Osaka University | 新規ヘキサトリエン-β-カルボニル化合物 |
| WO2010055950A1 (ja) | 2008-11-17 | 2010-05-20 | 財団法人ヒューマンサイエンス振興財団 | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 |
| JP5805363B2 (ja) * | 2009-06-26 | 2015-11-04 | 和興フィルタテクノロジー株式会社 | 可溶性凝集体、免疫寛容誘導剤及びその製造方法 |
| JP2012000072A (ja) * | 2010-06-18 | 2012-01-05 | Japan Health Science Foundation | 新規な抗フィブリン抗体 |
| AR086250A1 (es) * | 2011-05-05 | 2013-11-27 | Hoffmann La Roche | Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo |
-
2014
- 2014-02-27 EP EP18155006.2A patent/EP3339327A3/en active Pending
- 2014-02-27 US US14/770,864 patent/US9429584B2/en active Active
- 2014-02-27 JP JP2015503025A patent/JP6490574B2/ja active Active
- 2014-02-27 WO PCT/JP2014/054925 patent/WO2014133093A1/ja not_active Ceased
- 2014-02-27 EP EP14757745.6A patent/EP2963059B1/en active Active
- 2014-02-27 ES ES14757745.6T patent/ES2673583T3/es active Active
-
2018
- 2018-07-23 JP JP2018137861A patent/JP7012360B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3339327A2 (en) | 2018-06-27 |
| US9429584B2 (en) | 2016-08-30 |
| ES2673583T3 (es) | 2018-06-22 |
| JP2018193386A (ja) | 2018-12-06 |
| EP3339327A3 (en) | 2018-09-19 |
| JPWO2014133093A1 (ja) | 2017-02-02 |
| EP2963059A4 (en) | 2017-03-22 |
| JP7012360B2 (ja) | 2022-02-14 |
| US20160011217A1 (en) | 2016-01-14 |
| EP2963059A1 (en) | 2016-01-06 |
| EP2963059B1 (en) | 2018-04-04 |
| WO2014133093A1 (ja) | 2014-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6490574B2 (ja) | 不溶性フィブリンに対する抗体 | |
| CA2646329C (en) | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting | |
| US8101713B2 (en) | Prostate cancer diagnosis and treatment | |
| BR112012029281B1 (pt) | anticorpo contra trop-2 humano, anticorpo monoclonal contra trop-2 humano, fragmento de anticorpo derivado de anticorpo, hibridoma, conjugado, composição farmacêutica, uso de composição farmacêutica, método para detectar um tumor e kit para tratar, diagnosticar ou detectar um tumor | |
| MX2011004684A (es) | Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor. | |
| ES2615387T3 (es) | Anticuerpos contra el antígeno 1 asociado al riñón y fragmentos de unión al antígeno de estos | |
| JP2013522167A (ja) | uPAR結合剤及びその使用方法 | |
| US6835549B2 (en) | Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma | |
| EP3387016A1 (en) | Antibodies for treatment and diagnosis of inflammatory bowel disease | |
| WO2011158973A1 (ja) | 新規な抗フィブリン抗体 | |
| TW201842938A (zh) | 可藉由胞漿素切斷之抗不溶性纖維蛋白抗體與藥物之複合體 | |
| WO2011090166A1 (ja) | 食道癌マーカー | |
| KR20140067047A (ko) | 대장암 또는 식도암의 검출용 마커 및 검사 방법 | |
| WO2016167227A1 (ja) | 不溶性フィブリンに対する抗体 | |
| WO2025040093A1 (zh) | 靶向gpc3的分子探针以及用途 | |
| KR20130135869A (ko) | 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제 | |
| KR101380057B1 (ko) | 췌장암의 진단제 및 치료제 | |
| US20140178906A1 (en) | Monoclonal antibodies against pcbp-1 antigens, and uses therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150907 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170906 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180605 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180723 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190118 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6490574 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |